NLRP3 and irritable bowel syndrome: BAY 11-7082 demonstrated a therapeutic effect also in IBS, significantly reducing the pathological signs of disease by inhibiting NLRP3 inflammasome activity and NF-κB translocation, thus reducing the release of inflammatory mediators [66].